ViewRay

ViewRay Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of ViewRay (VRAYQ) as of Oct 2, 2026 is 137.54. In the previous year, Cash Conversion Cycle (CCC) was 200.19 — a change of -31.30% (lower).

Cash Conversion Cycle

137.54

YoY

-31.30%

Last updated:

Cash Conversion Cycle (CCC) of ViewRay is 2026 137.54 . Cash Conversion Cycle (CCC) of ViewRay was 2025 200.19 . It decreases by -31.30% lower compared to the previous year.

The ViewRay Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2015
74.16 USD
Jan 1, 2016
95.75 USD
Jan 1, 2017
292.61 USD
Jan 1, 2018
341.25 USD
Jan 1, 2019
212.82 USD
Jan 1, 2020
277.81 USD
Jan 1, 2021
200.19 USD
Jan 1, 2022
137.54 USD
The ViewRay Cash Conversion Cycle history
YEARCash Conversion CycleYoY
137.54-31.30%
200.19-27.94%
277.81+30.54%
212.82-37.63%
341.25+16.62%
292.61+205.59%
95.75+29.12%
74.16+44.20%
51.42—
Access this data via the Eulerpool API

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViewRay stock

Cash Conversion Cycle (CCC) of ViewRay is 137.54 in 2026.

Cash Conversion Cycle (CCC) of ViewRay changed from 200.19 to 137.54, representing a -31.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) ViewRay since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s ViewRay with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — ViewRay

All Key Metrics — ViewRay